[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 58 of about 58
1. López JI: Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation. BJU Int; 2007 Dec;100(6):1272-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation.
  • OBJECTIVE: To review specific histological variables in patients with prostate cancer who previously had diagnoses of high-grade prostatic intraepithelial neoplasia (HGPIN) and/or atypical small acinar proliferation (ASAP), compared with those who had no such diagnoses.
  • Similarly, patients with these previous diagnoses had a lower Gleason score (P = 0.017 and <0.001, respectively) and lower tumour volume variables (fewer tumour foci, P = 0.033 and 0.041, respectively) and shorter cancer (P = 0.048 and 0.030) in core biopsies than those without.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Cell Proliferation. Humans. Immunohistochemistry. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850386.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Svrcek M, Lesurtel M, Lewin M, Afchain P, Fabre M, Scoazec JY, Parc R, Fléjou JF: [Acinar cell carcinoma of the pancreas with predominant intraductal growth: report of a case]. Gastroenterol Clin Biol; 2007 May;31(5):543-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinar cell carcinoma of the pancreas with predominant intraductal growth: report of a case].
  • [Transliterated title] Carcinome à cellules acineuses du pancréas, de développement essentiellement intracanalaire: à propos d'un cas.
  • Acinar cell carcinoma (ACC) of the pancreas accounts for approximately 1% of all exocrine pancreatic tumours.
  • This tumour was revealed by epigastric pain and weight loss.
  • There was a marked dilatation of the main pancreatic duct upstream, with tumour spreading within this duct.
  • On the pancreaticoduodenectomy specimen, the dilated main pancreatic duct (2.5 cm in diameter) was filled by an exophytic tumour.
  • These rare forms of ACC can be confused with intraductal papillary-mucinous neoplasms.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Pancreatic Ducts / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Endosonography. Humans. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Radiography, Abdominal. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541347.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Mäkinen K, Loimas S, Hakala T, Eskelinen M: Tumour suppressor protein (p53), apoptosis inhibiting protein (Bcl-2) and proliferating cell nuclear antigen (PCNA) expressions in a rat pancreatic tumour model. Anticancer Res; 2007 Jan-Feb;27(1A):23-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour suppressor protein (p53), apoptosis inhibiting protein (Bcl-2) and proliferating cell nuclear antigen (PCNA) expressions in a rat pancreatic tumour model.
  • BACKGROUND: Previous studies have shown that, cultured rat pancreatic carcinoma cells, derived from azaserine-induced acinar tumours, yield tumours with a ductal phenotype.
  • MATERIALS AND METHODS: In order to find out the molecular characteristics of this tumour model, tumour suppressor protein (p53), apoptosis inhibiting protein (Bcl-2) and proliferating cell nuclear antigen (PCNA) expressions were analysed in rat pancreatic and subcutaneous tumours, as well as in normal rat pancreas.
  • Bcl-2 did not show positive immunoreactivity in rat tumour samples.
  • For PCNA all tumour samples showed positive staining.
  • CONCLUSION: Possible mutations in the p53 tumour suppressor gene and a strong expression of PCNA were shown in carcinoma cell line-induced rat pancreatic tumours.
  • These features of the rat pancreatic tumour model resemble human pancreatic carcinoma and may favour the use of this model in pancreatic cancer studies.
  • [MeSH-major] Pancreatic Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352211.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


Advertisement
4. Calafat M, Larocca L, Roca V, Hauk V, Pregi N, Nesse A, Pérez Leirós C: Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands. Arthritis Res Ther; 2009;11(2):R53
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands.
  • Our goal was to analyse the effect of TNF-alpha on apoptotic mediators in isolated acinar cells from NOD submandibular gland and their modulation by VIP.
  • METHODS: Acinar cells were isolated from submandibular glands of 16-week-old NOD females with salivary flow decline.
  • VIP effects in acinar cells were assessed at 100 nM in TNF-alpha-treated cultures and VIP receptor functional assays by radio immunoassay (cAMP) or enzymatic detection (amylase).
  • RESULTS: NOD acinar cells at 16 weeks present an increased expression of TNF-alpha receptor1 together with increased Bax, tumour protein 53-induced nuclear protein1alpha (TP53INP1alpha), caspase 3 activity and chromatin condensation.
  • CONCLUSIONS: Our results indicate that acinar cells isolated from submandibular glands of NOD mice with salivary dysfunction are more sensitive to apoptosis induced by TNF-alpha which could be prevented by VIP through a PKA-mediated pathway.
  • [MeSH-major] Apoptosis / physiology. Sjogren's Syndrome / metabolism. Submandibular Gland / metabolism. Tumor Necrosis Factor-alpha / metabolism. Vasoactive Intestinal Peptide / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2006 Jul;1070:525-30 [16888219.001]
  • [Cites] Biochim Biophys Acta. 2006 Feb;1763(2):238-46 [16500719.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 May;2(5):252-61 [16932698.001]
  • [Cites] Rheumatology (Oxford). 2006 Sep;45(9):1077-86 [16522680.001]
  • [Cites] Lab Invest. 2006 Dec;86(12):1243-60 [17075579.001]
  • [Cites] Reproduction. 2006 Dec;132(6):931-8 [17127753.001]
  • [Cites] Nat Rev Immunol. 2007 Jan;7(1):52-63 [17186031.001]
  • [Cites] Int Immunopharmacol. 2007 Oct;7(10):1343-9 [17673149.001]
  • [Cites] Peptides. 2007 Sep;28(9):1825-32 [17706836.001]
  • [Cites] Arthritis Rheum. 2007 Nov;56(11):3588-600 [17968930.001]
  • [Cites] Neuroimmunomodulation. 2007;14(3-4):134-8 [18073504.001]
  • [Cites] Neuroimmunomodulation. 2007;14(3-4):175-81 [18073511.001]
  • [Cites] Arthritis Res Ther. 2008;10(1):R22 [18289371.001]
  • [Cites] Arthritis Res Ther. 2008;10(6):R137 [19032782.001]
  • [Cites] Baillieres Best Pract Res Clin Rheumatol. 2000 Mar;14(1):73-95 [10882215.001]
  • [Cites] J Immunol. 2001 Jan 15;166(2):1028-40 [11145682.001]
  • [Cites] J Autoimmun. 2001 Sep;17(2):141-53 [11591123.001]
  • [Cites] Eur J Pharmacol. 2002 Mar 29;439(1-3):27-33 [11937089.001]
  • [Cites] Clin Immunol. 2002 May;103(2):111-24 [12027416.001]
  • [Cites] Arch Oral Biol. 2002 Jun;47(6):443-8 [12102760.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36676-87 [12867423.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37722-9 [12851404.001]
  • [Cites] Endocrinology. 2004 Jan;145(1):418-25 [14500572.001]
  • [Cites] Bull Rheum Dis. 1979-1980;30(9):1046-52 [398729.001]
  • [Cites] Semin Arthritis Rheum. 1984 Nov;14(2):77-105 [6399627.001]
  • [Cites] In Vitro Cell Dev Biol. 1988 Apr;24(4):266-73 [3284875.001]
  • [Cites] Proc Finn Dent Soc. 1989;85(4-5):323-31; discussion 361-3 [2699762.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5152-61 [8652828.001]
  • [Cites] Arthritis Rheum. 1997 Jan;40(1):87-97 [9008604.001]
  • [Cites] Lancet. 1997 Jun 21;349(9068):1814-5 [9269222.001]
  • [Cites] J Clin Invest. 1997 Oct 1;100(7):1853-62 [9312187.001]
  • [Cites] Clin Immunol Immunopathol. 1998 Aug;88(2):133-41 [9714690.001]
  • [Cites] Clin Exp Rheumatol. 1998 Nov-Dec;16(6):675-81 [9844759.001]
  • [Cites] Int Immunopharmacol. 2004 Dec 20;4(14):1837-44 [15531299.001]
  • [Cites] Br J Pharmacol. 2004 Dec;143(8):1058-65 [15533891.001]
  • [Cites] Immunology. 2005 May;115(1):1-20 [15819693.001]
  • [Cites] Clin Exp Immunol. 2005 Dec;142(3):411-8 [16297151.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8093-104 [16044147.001]
  • [Cites] Ann Rheum Dis. 2006 Feb;65(2):195-200 [15975969.001]
  • [Cites] Arthritis Rheum. 2006 Jul;54(7):2300-5 [16802370.001]
  • (PMID = 19356238.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 37221-79-7 / Vasoactive Intestinal Peptide; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  • [Other-IDs] NLM/ PMC2688204
  •  go-up   go-down


5. Chiaravalli AM, Finzi G, Bertolini V, La Rosa S, Capella C: Colonic carcinoma with a pancreatic acinar cell differentiation. A case report. Virchows Arch; 2009 Dec;455(6):527-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic carcinoma with a pancreatic acinar cell differentiation. A case report.
  • A case of a colonic carcinoma showing a pancreatic acinar cell differentiation is described for the first time.
  • A 65-year-old woman underwent surgical resection for an ulcerated protruding tumour of 4 x 2.5 cm in size on the anterior wall of the sigmoid colon.
  • Histologically, tumour cells were organized in acinar structures resembling pancreatic acini and in solid nests and ribbons or diffusely infiltrated as poorly cohesive cells.
  • The ultrastructural analysis of the primary tumour indicated the presence of zymogen-like granules in the cytoplasm of tumour cells.
  • Immunohistochemically, both acinar and diffuse patterns of growth showed an intense staining for trypsin, chymotrypsin and BCL10 and a weaker immunoreactivity for lipase and carboxyl ester hydrolase.
  • Most tumour cells were cytokeratin 20, CDX2 and p53 positive; whereas, mucin (MUC)2 immunoreactivity was observed only in the signet ring cells present in the diffuse pattern and chromogranin A in rare isolated tumour cells.
  • There was no evidence of a pancreatic acinar cell carcinoma or of heterotopic pancreatic tissue.
  • A colonic origin ought to be suspected when a metastatic carcinoma of unknown primary shows an acinar differentiation.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Colonic Neoplasms / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. CDX2 Transcription Factor. Cell Differentiation. Fatal Outcome. Female. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Keratin-20 / metabolism. Lymphatic Metastasis. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1996 Mar;122(3):983-95 [8631275.001]
  • [Cites] Virchows Arch. 2009 Feb;454(2):133-42 [19066953.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):649-54 [16865281.001]
  • [Cites] Differentiation. 1992 Sep;51(1):55-60 [1451962.001]
  • [Cites] J Pathol. 2006 Jun;209(2):147-56 [16691544.001]
  • [Cites] Stem Cells. 2008 Apr;26(4):874-85 [18238854.001]
  • [Cites] Pathobiol Annu. 1979;9:163-204 [384335.001]
  • [Cites] Eur J Biochem. 1990 Sep 11;192(2):543-50 [1698625.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Gut. 2004 Mar;53(3):323-30 [14960508.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1524-9 [16224221.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Hum Pathol. 2002 May;33(5):569-73 [12094386.001]
  • [Cites] Gastrointest Endosc. 1997 Aug;46(2):172-6 [9283871.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):619-25 [8552090.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):141-9 [12548159.001]
  • [Cites] J Pathol. 2003 Feb;199(2):176-84 [12533830.001]
  • [Cites] APMIS. 1995 Jan;103(1):69-78 [7695893.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • (PMID = 19908063.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


6. Vidyadhara S, Shetty AP, Rajasekaran S: Widespread metastases from acinic cell carcinoma of parotid gland. Singapore Med J; 2007 Jan;48(1):e13-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Widespread metastases from acinic cell carcinoma of parotid gland.
  • Acinic cell carcinoma metastasising to the spine is rare and has been described only once before in the literature.
  • We believe this 40-year-old man to be the first reported case of incompletely resected acinic cell carcinoma of the parotid gland metastasising simultaneously to regional lymph nodes, upper lobes of both lungs, sphenoid bone and dorsal spine with neurological deficits.
  • This case report stresses the need for postoperative radiotherapy following incomplete resection of the primary tumour.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Lung Neoplasms / secondary. Parotid Neoplasms / pathology. Skull Neoplasms / secondary. Sphenoid Bone. Spinal Neoplasms / secondary. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245497.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


7. Komorski JA, Nienartowicz JM: [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis]. Otolaryngol Pol; 2009 Sep-Oct;63(5):442-7
Genetic Alliance. consumer health - Acinic Cell Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis].
  • [Transliterated title] Acinic cell carcinoma ślinianki przyusznej o nietypowym obrazie klinicznym i niekorzystnym przebiegu.
  • In the case of neck tumours, these are unfortunately late signs, but in patients with a primary neoplastic focus within the head and neck, neck tumour is often the first sign of the disease.
  • The authors describe a clinical case of neck tumour with initially unclear etiology.
  • The preoperative diagnostics including ultrasonography, thin-needle puncture, MRI, carotid angiography and videostroboscopy was significant for surgical treatment planning; yet it was the intraoperative clinical picture which indicated that the tumour derived from the inferior parotid pole.
  • The histopathological examination confirmed non-cornifying basal cell epithelioma only in the essential lesion with no metastases to lymph nodes and surrounding tissue margins free of infiltrates.
  • Two and a half years after the procedure, the patient presented with a tumour localized on the front thoracic wall and two rapidly enlarging tumours in the nape of the neck.
  • In the collected specimen of the tumour on the front thoracic wall, a diagnosis of acinic cell carcinoma was made.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery
  • [MeSH-minor] Aged. Head and Neck Neoplasms / secondary. Humans. Male. Neck Dissection / methods. Neoplasm Staging. Palliative Care. Prognosis. Thoracic Wall / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169911.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


8. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • Ten acinar adenocarcinomas of varying grades were also immunostained as controls.
  • Protein and mRNA expression were 2+ to 3+ (of 3+) in all patients with ACBCC, compared to a breast cancer control with strong reactivity, whereas protein expression was noted in only one acinar carcinoma and mRNA expression was absent in all acinar carcinomas.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Gene Expression. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics


9. de Dios I, Ramudo L, García-Montero AC, Manso MA: Redox-sensitive modulation of CD45 expression in pancreatic acinar cells during acute pancreatitis. J Pathol; 2006 Oct;210(2):234-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Redox-sensitive modulation of CD45 expression in pancreatic acinar cells during acute pancreatitis.
  • CD45, a transmembrane protein tyrosine phosphatase required for signal transduction in leukocytes, has recently been found in pancreatic acinar cells.
  • We have investigated the relationship between kinetic expression of CD45 on acinar cells during acute pancreatitis (AP) and the ability of these cells to produce tumour necrosis factor-alpha (TNF-alpha) through mechanisms sensitive to the cellular redox state.
  • Flow cytometric analysis showed a significant decrease in the constitutive expression of CD45 in acinar cells from six hours onwards after inducing AP by bile-pancreatic duct obstruction (BPDO) in parallel with a significant increase in acinar TNF-alpha production.
  • Changes in protein expression on the acinar cell surface preceded CD45 mRNA down-regulation, which was not found until 12 hours after BPDO.
  • N-Acetylcysteine treatment delayed and reduced the down-regulation of CD45 expression induced by AP and prevented acinar cells from producing TNF-alpha.
  • Our results show that CD45 expression is down-regulated in acinar cells during acute pancreatitis by redox-sensitive mechanisms, and they support the notion that CD45 negatively controls the production of cytokines in pancreatic acinar cells.
  • [MeSH-minor] Acute Disease. Animals. Cells, Cultured. Down-Regulation. Flow Cytometry / methods. Gene Expression. Humans. Male. Oxidation-Reduction. RNA, Messenger / genetics. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Necrosis Factor-alpha / biosynthesis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886168.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


10. Sorscher SM: Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report. Eur J Cancer Care (Engl); 2009 May;18(3):318-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
  • Acinar cell carcinoma of the pancreas is rare tumour with a generally poor prognosis.
  • There are very few reports of tumour regression following chemotherapy.
  • In this case report, a patient with metastatic acinar cell carcinoma in the liver developed progressive disease after cisplatin/etoposide and then had progressive disease after weekly paclitaxel chemotherapy.
  • However, his tumour then responded to gemcitibine/5-flourouracil/leucovorin chemotherapy.
  • Herein, previously described chemotherapy regimens used for this rare tumour are reviewed.
  • This case represents the first reported metastatic acinar cell carcinoma responding to this regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Liver Neoplasms / drug therapy. Pancreatic Neoplasms
  • [MeSH-minor] Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Treatment Outcome. Vitamin B Complex / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445023.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 12001-76-2 / Vitamin B Complex; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Mallén E, Gil P, Sancho C, Jesús Gil M, Allepuz C, Borque A, Del Agua C, Angel Rioja L: Atypical small acinar proliferation: review of a series of 64 patients. Scand J Urol Nephrol; 2006;40(4):272-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation: review of a series of 64 patients.
  • OBJECTIVE: To study the evolution of 64 patients initially diagnosed with ASAP (atypical small acinar proliferation).
  • In these 20 patients, the median tumour volume was 0.4 cm3 (range 0.1-3.2 cm3) and 44% of the tumours were significant.
  • [MeSH-minor] Aged. Biopsy. Cell Proliferation. Humans. Male. Prostate-Specific Antigen / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916766.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


12. Luebke AM, Schlomm T, Gunawan B, Bonkhoff H, Füzesi L, Erbersdobler A: Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach. Virchows Arch; 2005 Mar;446(3):338-41
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.
  • Basal cell tumours of the prostatic gland are rare, and the classification is difficult.
  • In the present case report, a large, tumour-like proliferation of atypical basaloid cells was found incidentally in a prostatectomy specimen that otherwise contained a conventional acinar adenocarcinoma.
  • However, there were no definite criteria for a malignant behaviour of the basal cell tumour.
  • Comparative genomic hybridisation from microdissected tumour cells yielded losses at the short arms of chromosomes 8 and 12 in the conventional adenocarcinoma and a normal karyotype in the basal cell tumour.
  • The pathological findings favoured the diagnosis of an atypical basal cell hyperplasia.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Carcinoma, Acinar Cell / pathology. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / complications. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1993 Aug;117(8):799-801 [8343043.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):342-7 [7529134.001]
  • [Cites] Eur Urol. 1999;36(1):21-30 [10364651.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):668-72 [14999772.001]
  • [Cites] Histopathology. 1992 Feb;20(2):151-5 [1559669.001]
  • [Cites] Pathol Res Pract. 1990 Feb;186(1):28-36 [2179908.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):787-91 [14756145.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1425-33 [2461340.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1523-9 [14657711.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):43-51 [12107088.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1225-33 [2400973.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1447-50 [9865831.001]
  • (PMID = 15726402.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Sabbagh C, Fuks D, Chatelain D, Flamant M, Delcenserie R, Yzet T, Regimbeau JM: [Acinar cell carcinoma of the pancreas: a rare tumor with particular clinical and paraclinical presentation]. Rev Med Interne; 2008 Dec;29(12):1046-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinar cell carcinoma of the pancreas: a rare tumor with particular clinical and paraclinical presentation].
  • Acinar cell carcinoma of the pancreas is a rare tumour with specific clinical and paraclinical presentation.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433943.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Hsu MY, Pan KT, Chu SY, Hung CF, Wu RC, Tseng JH: CT and MRI features of acinar cell carcinoma of the pancreas with pathological correlations. Clin Radiol; 2010 Mar;65(3):223-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT and MRI features of acinar cell carcinoma of the pancreas with pathological correlations.
  • AIM: To document the computed tomography (CT) and magnetic resonance imaging (MRI) features of acinar cell carcinoma of the pancreas and to correlate them with pathological findings to determine the unique imaging manifestations of this rare subtype tumour of the pancreas.
  • MATERIALS AND METHODS: From January 1986 to August 2008, six patients (five men and one woman, mean age 61.3 years) with histologically proven acinar cell carcinoma of the pancreas underwent CT (n=6) and MRI (n=4) examinations.
  • The imaging features of each tumour were documented and compared with pathological findings.
  • Two tumours (33%) exhibited intratumoural haemorrhage, and one tumour (17%) had amorphous intratumoural calcification.
  • CONCLUSION: Acinar cell carcinoma of the pancreas has distinct imaging features, and both CT and MRI are useful and complementary imaging methods.
  • [MeSH-major] Carcinoma, Acinar Cell. Magnetic Resonance Imaging. Pancreatic Neoplasms. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20152279.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


15. Abasolo I, Pujal J, Rabanal RM, Serafin A, Navarro P, Millán O, Real FX: FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours. Eur J Nucl Med Mol Imaging; 2009 Jul;36(7):1156-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours.
  • PURPOSE: The aim was to evaluate FDG PET imaging in Ela1-myc mice, a pancreatic cancer model resulting in the development of tumours with either acinar or mixed acinar-ductal phenotype.
  • RESULTS: Transversal studies showed that mixed acinar-ductal tumours could be identified by FDG PET several weeks before they could be detected by hand palpation.
  • Longitudinal studies revealed that ductal--but not acinar--tumours could be detected by FDG PET.
  • Autoradiographic analysis confirmed that tumour areas with ductal differentiation incorporated more FDG than areas displaying acinar differentiation.
  • Ex vivo radioactivity measurements showed that tumours of solely acinar phenotype incorporated more FDG than pancreata of non-transgenic littermates despite the fact that they did not yield positive PET images.
  • To gain insight into the biological basis of the differential FDG uptake, glucose transporter and hexokinase transcript expression was studied in microdissected tumour areas enriched for acinar or ductal cells and validated using cell-specific markers.
  • Glut2 and hexokinase I and II mRNA levels were up to 20-fold higher in ductal than in acinar tumours.
  • CONCLUSION: In Ela1-myc mice, ductal tumours incorporate significantly more FDG than acinar tumours.
  • These findings reveal previously unreported biological differences between acinar and ductal pancreatic tumours.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnostic imaging. Carcinoma, Acinar Cell / metabolism. Carcinoma, Pancreatic Ductal / diagnostic imaging. Carcinoma, Pancreatic Ductal / metabolism. Fluorodeoxyglucose F18 / metabolism. Genes, myc

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Carcinog. 2006 Jul 05;5:19 [16822304.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):237-42 [11926386.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1129-39 [15466380.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] J Nucl Med. 2001 May;42(5):721-5 [11337566.001]
  • [Cites] Nucl Med Biol. 2001 Jan;28(1):1-4 [11182558.001]
  • [Cites] Int Rev Cytol. 1992;137:209-38 [1428671.001]
  • [Cites] J Nucl Med. 2008 Aug;49(8):1362-70 [18632830.001]
  • [Cites] Gastroenterology. 2008 Sep;135(3):724-8 [18692502.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Feb;20(1):3-21 [16473798.001]
  • [Cites] Scand J Gastroenterol. 2000 Aug;35(8):883-8 [10994629.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 9;288(4):882-6 [11688991.001]
  • [Cites] J Nucl Med. 1998 Oct;39(10 ):1727-35 [9776278.001]
  • [Cites] Exp Cell Res. 2007 Sep 10;313(15):3337-48 [17651733.001]
  • [Cites] J Cell Physiol. 2005 Mar;202(3):654-62 [15389572.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(1):4-10 [15747028.001]
  • [Cites] Pancreatology. 2008;8(4-5):462-9 [18724072.001]
  • [Cites] Int J Oncol. 2001 Jul;19(1):53-8 [11408922.001]
  • [Cites] Cancer Res. 2001 May 15;61(10 ):3853-7 [11358795.001]
  • [Cites] Cancer Biol Ther. 2004 Feb;3(2):170-2 [15034301.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1958-64 [12806629.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):737-47 [12536244.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):328-34 [15509640.001]
  • [Cites] Nucl Med Biol. 2005 Jul;32(5):445-50 [15982574.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):93-7 [1986386.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Jun;16(3):421-33 [12079267.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):379-87 [11786564.001]
  • [Cites] Br J Biomed Sci. 2000;57(2):170-8 [10912295.001]
  • [Cites] Nucl Med Biol. 1998 May;25(4):317-22 [9639291.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):849-55 [17332923.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:65-72 [16869739.001]
  • (PMID = 19252908.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / elongin; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.1.1 / Hexokinase
  •  go-up   go-down


16. Chetty R, Serra S, Asa SL, Volkan Adsay N: Pancreatic endocrine tumour with ductules: further observations of an unusual histological subtype. Pathology; 2006 Feb;38(1):5-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumour with ductules: further observations of an unusual histological subtype.
  • Opinions range from the ductules being an inherent part of the tumour, to others who feel they are merely entrapped.
  • A study of 21 cases of this variant was undertaken with particular attention paid to the distribution and morphology of the ductules, the presence of entrapped acinar tissue and the surrounding uninvolved pancreatic tissue.
  • The ductules were centrally located (5), at the periphery of the tumour (9) or diffusely scattered throughout the lesion (7).
  • CONCLUSIONS: It is likely that in some cases the ductules are entrapped as the tumour grows into surrounding normal pancreatic tissue and the ductular proliferation is a secondary phenomenon.
  • In a proportion of cases, the ductules are likely to be a part of the tumour arising as part of focal chronic inflammation or as a result of the growth factor effects of insulin, in cases associated with insulin production.
  • [MeSH-major] Carcinoma, Islet Cell / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484000.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Insulin; 68238-35-7 / Keratins
  •  go-up   go-down


17. Mocan S, Stolnicu S, Rădulescu D, Petrovan C: [Acinic cell adenocarcinoma of the lip]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):164-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell adenocarcinoma of the lip].
  • [Transliterated title] Adenocarcinom cu celule acinare cu localizare la nivelul buzei. Prezentare de caz.
  • The variable histological appearance of acinic cell carcinoma coupled with its uncommon occurrence account for considerable diagnostic difficulties.
  • The tumour mass was excised, fixed in formaline, embedded in paraffin and the sections were stained with Haematoxylin-Eosin, PAS-Haematoxylin, PAS-Alcian blue and Perls.
  • The tumour was nodular, well circumscribed, with a cystic appearance on the cut surface.
  • Microscopically, the tumour had a papillary-cystic growth, with one large cystic space lined by epithelium of variable thickness and branching projections of epithelium occupying a large portion of the cyst's lumen.
  • Different cellular features were recognised in the tumour, with the presence of both serous and mucous acinar differentiation.
  • Acinic cell adenocarcinoma is a malignant epithelial neoplasm in which the neoplastic cells demonstrate not only serous acinar differentiation.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Lip Neoplasms / pathology. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607848.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


18. Wu H, Bhopale KK, Ansari GA, Kaphalia BS: Ethanol-induced cytotoxicity in rat pancreatic acinar AR42J cells: role of fatty acid ethyl esters. Alcohol Alcohol; 2008 Jan-Feb;43(1):1-8
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethanol-induced cytotoxicity in rat pancreatic acinar AR42J cells: role of fatty acid ethyl esters.
  • METHODS: A time- and concentration-dependent synthesis of FAEEs and the cytotoxicity of ethanol and its predominant fatty acid esters were studied in rat pancreatic tumour (AR42J) cells in cultures.
  • RESULTS: The levels of FAEEs synthesized in cell cultures incubated with 800 mg% ethanol for 6 h were approximately 10-fold higher (60 nmol/25 x 10(6) cells) than those in cells incubated with 100 mg% ethanol (5.4 nmol/25 x 10(6) cells).
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / physiology. Cell Line, Tumor. Dose-Response Relationship, Drug. Esters. Humans. Rats

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942438.001).
  • [ISSN] 1464-3502
  • [Journal-full-title] Alcohol and alcoholism (Oxford, Oxfordshire)
  • [ISO-abbreviation] Alcohol Alcohol.
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / AA13171; United States / NIEHS NIH HHS / ES / P30ES06676
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Esters; 0 / Fatty Acids; 3K9958V90M / Ethanol
  •  go-up   go-down


19. Chidzonga MM, Makunike-Mutasa R: Acinic cell carcinoma of the submandibular salivary gland presenting as a large cyst. Int J Oral Maxillofac Surg; 2007 Dec;36(12):1215-7
Genetic Alliance. consumer health - Acinic Cell Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the submandibular salivary gland presenting as a large cyst.
  • Acinic cell carcinomas are rare tumours of salivary gland origin, most commonly seen in middle-aged women and predominantly in the parotid gland.
  • The case of a long-standing, predominantly cystic, acinic cell carcinoma located in the submandibular gland of a child is presented here.
  • The tumour was successfully removed and there has been no recurrence.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Submandibular Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629459.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


20. Elcombe CR, Elcombe BM, Foster JR, Farrar DG, Jung R, Chang SC, Kennedy GL, Butenhoff JL: Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARα and CAR/PXR. Arch Toxicol; 2010 Oct;84(10):787-98
Hazardous Substances Data Bank. Perfluorooctanoic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARα and CAR/PXR.
  • Although non-genotoxic, chronic dietary treatment of Sprague-Dawley (S-D) rats with APFO produced an increase in benign tumours of the liver, acinar pancreas, and testicular Leydig cells.
  • The present study evaluates the potential roles for APFO-induced activation of PPARα and CAR/PXR with respect to liver tumour production in the S-D rat and when compared to the specific PPARα agonist, 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (Wy 14,643).
  • Responses to treatment with Wy 14,643 were consistent with increased activation of PPARα, specifically: increased CYP4A1 and peroxisomal β-oxidation; increased hepatocellular hypertrophy and cell proliferation; decreased apoptosis; and hypolipidaemia.
  • [MeSH-major] Caprylates / toxicity. Cell Proliferation / drug effects. Environmental Pollutants / toxicity. Fluorocarbons / toxicity. Hepatocytes / drug effects. Receptors, Cytoplasmic and Nuclear / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20614104.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Caprylates; 0 / Environmental Pollutants; 0 / Fluorocarbons; 0 / PPAR alpha; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / constitutive androstane receptor; 0 / pregnane X receptor; 9007-49-2 / DNA; 9035-51-2 / Cytochrome P-450 Enzyme System; 947VD76D3L / perfluorooctanoic acid
  •  go-up   go-down


21. Michail P, Karavokyros I, Pikoulis E, Arvelakis A, Charminis G, Michail O, Theodoros D: Acinic cell carcinoma of the parotid gland in children: a case report and literature review. West Indian Med J; 2008 Jan;57(1):70-2
Genetic Alliance. consumer health - Acinic Cell Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the parotid gland in children: a case report and literature review.
  • Parotid acinic cell carcinoma is a rare malignancy in childhood.
  • Tumour resection revealed acinic cell carcinoma of the parotid gland.
  • We review the literature on acinic cell carcinomas of parotid glands in childhood.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19565943.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Jamaica
  • [Number-of-references] 26
  •  go-up   go-down


22. Cho JH, Yoon SY, Bae EY, Lee CN, Lee JD, Cho SH: Acinic cell carcinoma on the lower lip resembling a mucocele. Clin Exp Dermatol; 2005 Sep;30(5):490-3
Genetic Alliance. consumer health - Acinic Cell Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma on the lower lip resembling a mucocele.
  • Histopathological examination showed a well-circumscribed tumour composed of many lobules separated by thin, fibrous connective tissue.
  • Individual lobules were composed of round or polyhedral tumour cells, which had a characteristic finely granular and vacuolated cytoplasm and eccentric hyperchromatic nuclei.
  • Positive staining was observed with Periodic acid-Shiff, and immunohistochemistry for cytokeratin, alpha-1 antitrypsin, and S-100 protein resulting in a final diagnosis of acinic cell carcinoma.
  • Acinic cell carcinoma represents a well-established, although uncommon, entity in the classification of neoplasms of salivary gland origin.
  • The parotid salivary gland is the most frequent site of acinic cell carcinoma, whereas the lip is a particularly unusual site.
  • The unusual presentation of this tumour may lead to confusion with a mucocele.
  • Given these findings, we suggest that acinic cell carcinoma should be considered in the differential diagnosis of any mucocele-like mass on the lower lip.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Lip Neoplasms / pathology. Mucocele / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045674.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Tavernier L, Godon A, Algros MP, Rainfaing E, Chobaut JC: [Acinic cell carcinoma in an ectopic salivary gland]. Rev Laryngol Otol Rhinol (Bord); 2010;131(4-5):299-302
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma in an ectopic salivary gland].
  • On the occasion of the coverage of a cervical tumefaction in a child, which led to the diagnosis of acinic cell carcinoma of ectopic salivary gland, the authors conducted a literature review of this tumour.
  • From a histological point of view it is difficult to distinguish, if primitive location, the occurrence of the tumour in an ectopic salivary gland, its occurrence in intra-node heterotopic salivary tissue.
  • This one remains empirical and discussed on a case-by-case basis for a malignant tumour that is exceptional in this location and at that age.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Choristoma / pathology. Mandibular Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21866744.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature; 2008 Mar 13;452(7184):187-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis.
  • Mechanisms underlying global changes in gene expression during tumour progression are poorly understood.
  • RNA-interference-mediated knockdown of SATB1 in highly aggressive (MDA-MB-231) cancer cells altered the expression of >1,000 genes, reversing tumorigenesis by restoring breast-like acinar polarity and inhibiting tumour growth and metastasis in vivo.
  • Conversely, ectopic SATB1 expression in non-aggressive (SKBR3) cells led to gene expression patterns consistent with aggressive-tumour phenotypes, acquiring metastatic activity in vivo.
  • SATB1 delineates specific epigenetic modifications at target gene loci, directly upregulating metastasis-associated genes while downregulating tumour-suppressor genes.
  • SATB1 reprogrammes chromatin organization and the transcription profiles of breast tumours to promote growth and metastasis; this is a new mechanism of tumour progression.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Gene Expression Regulation, Neoplastic / genetics. Matrix Attachment Region Binding Proteins / metabolism. Neoplasm Metastasis / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Line. Cell Line, Tumor. Cell Polarity. Disease Progression. Epigenesis, Genetic / genetics. Gene Expression Profiling. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secretion. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / genetics. Lymphatic Metastasis / pathology. Mice. Mice, Nude. Neoplasm Transplantation. Phenotype. Prognosis. RNA Interference


25. Ebert C, Nebe B, Walzel H, Weber H, Jonas L: Inhibitory effect of the lectin wheat germ agglutinin (WGA) on the proliferation of AR42J cells. Acta Histochem; 2009;111(4):335-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rat pancreatic acinar tumour cell line AR42J is a widely used model to study the secretion, proliferation and differentiation of cells under the influence of hormones.
  • They possess both subtypes of the highly glycosylated cholecystokinin (CCK) receptor which are important for the regulation of secretion and for cell growth.
  • [MeSH-major] Cell Proliferation / drug effects
  • [MeSH-minor] Animals. Cell Line, Tumor. Flow Cytometry. Galectin 1 / pharmacology. Glycosylation / drug effects. Humans. Microscopy, Electron, Transmission. Pancreas / pathology. Pancreas / ultrastructure. Plant Lectins / pharmacology. Rats. Receptors, Cholecystokinin / chemistry. Secretory Vesicles / ultrastructure. Wheat Germ Agglutinins / pharmacology. alpha-Amylases / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19195686.001).
  • [ISSN] 1618-0372
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Galectin 1; 0 / Plant Lectins; 0 / Receptors, Cholecystokinin; 0 / Ulex europaeus lectins; 0 / Wheat Germ Agglutinins; EC 3.2.1.1 / alpha-Amylases
  •  go-up   go-down


26. Bandyopadhyay A, Das TK, Raha K, Hati GC, Mitra PK, Dasgupta A: A study of fine needle aspiration cytology of salivary gland lesions with histopathological corroboration. J Indian Med Assoc; 2005 Jun;103(6):312-4, 316
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All smears were evaluated according to cell size, amount of cytoplasm, cytologic atypia and presence of lymphocytes. (a) Variable cytologic appearances of pleomorphic salivary adenoma were observed. (b) Cellular pleomorphic adenoma and adenoid cystic carcinoma showed basaloid cell features. (c) Tumours with intermediate size cells and bland cytology included low grade muco-epidermoid carcinoma and cystic lesions. (d) Warthin's tumour, oncocytoma, salivary duct carcinoma and high grade muco-epidermoid carcinoma revealed large cells and abundant cytoplasm with or without atypia.
  • A major diagnostic categories were inflammatory lesions (n = 7 5), cystic lesions (n = 9), benign tumours (n = 81), malignant neoplasms (n = 1 8) and normal acinar pattern (n = 2).
  • Malignant tumours included muco-epidermoid carcinoma (n = 5), adenoid cystic carcinoma (n = 3), acinic cell carcinoma (n = 2), adenocarcinoma (n= 2), squamous cell carcinoma (n = 1), undifferentiated carcinoma (n= 4) and malignant lymphoma (n = 1).
  • Histopathological correlation was possible in 40% of benign and 80% of malignant neoplasms.
  • [MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology. Sialadenitis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225156.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


27. Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P, Bahra M, Denkert C, Dietel M, Kristiansen G: Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology; 2005;5(2-3):259-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: PLK1 was found overexpressed in pancreatic neoplasia as early as in pancreatic intraepithelial neoplasia III lesions, whereas benign acinar pancreatic parenchyma and ductal epithelia showed only focal PLK1 positivity.
  • No correlation of PLK1 positivity and the extent of tumour spread was evident, nor did PLK1 expression correlate with tumour grade or patient prognosis.
  • Prognostic factors in our study cohort were nodal status and tumour grade.
  • [MeSH-major] Carcinoma in Situ / metabolism. Cell Cycle Proteins / metabolism. Pancreatic Neoplasms / metabolism. Protein Kinases / metabolism. Proto-Oncogene Proteins / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855824.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  •  go-up   go-down


28. Meer S, Altini M: CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology; 2007 Jul;51(1):26-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia.
  • AIMS: To evaluate cytokeratin (CK) 7/20 expression patterns in salivary gland neoplasia.
  • The tumours included pleomorphic adenoma (n = 24), myoepithelioma (n = 9), papillary cystadenoma (n = 3), oncocytoma (n = 2), adenoid cystic carcinoma (n = 22), mucoepidermoid carcinoma (n = 21), polymorphous low-grade adenocarcinoma (n = 21), carcinoma ex-pleomorphic adenoma (n = 11), acinic cell carcinoma (n = 17), epimyoepithelial carcinoma (n = 7), oncocytic carcinoma (n = 3), hyalinizing clear cell carcinoma (n = 1), papillary cystadenocarcinoma (n = 1), salivary duct carcinoma (n = 3), adenocarcinoma (not otherwise specified) (n = 4) and squamous carcinoma (n = 4).
  • The results were expressed semiquantitatively, according to the estimated percentage of positive tumour cells: 1+, 5-25%; 2+, 26-75%; and 3+, 76-100%.
  • All salivary gland neoplasms showed a CK7+/CK20- immunoprofile ranging from 5 to 100%.
  • CONCLUSIONS: Although the CK7/20 immunoprofile is not useful in distinguishing the various types of salivary gland neoplasms or between benign and malignant salivary gland tumours, it may facilitate differentiation of primary salivary gland neoplasia from metastatic tumours and squamous carcinoma, and the diagnosis of metastatic salivary gland tumours.
  • [MeSH-major] Gene Expression Profiling. Keratin-20 / metabolism. Keratin-7 / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Salivary Glands / metabolism. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593078.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


29. Mai KT, Kohler DM, Belanger EC, Robertson SJ, Wang D: Sporadic clear cell renal cell carcinoma with diffuse cytokeratin 7 immunoreactivity. Pathology; 2008 Aug;40(5):481-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic clear cell renal cell carcinoma with diffuse cytokeratin 7 immunoreactivity.
  • AIMS: Clear cell renal cell carcinoma (CRCC) with diffuse immunoreactivity for CK7 is described.
  • Areas of regenerative epithelial cell nests (REC) were also examined.
  • The CK7 positive CRCC measured less than 16 mm and contained varying proportions of tumour cells with chromophil cytoplasm.
  • Architecturally, CK7 positive CRCC consisted of cysts and solid cell nests with tubulo-acinar formations or papillary formations.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / metabolism. Keratin-7 / biosynthesis. Kidney Neoplasms / metabolism

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604734.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-7; EC 3.4.24.11 / Neprilysin; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


30. Quer M, Pujol A, León X, López M, García J, Orús C, Sañudo JR: Parotidectomies in benign parotid tumours: "Sant Pau" surgical extension classification. Acta Otorrinolaringol Esp; 2010 Jan-Feb;61(1):1-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION AND GOALS: At present different options co-exist for treating a benign tumour of the parotid gland, which has led to some confusion about the extent of resection performed in each case.
  • [MeSH-major] Adenolymphoma / surgery. Adenoma / surgery. Oral Surgical Procedures / classification. Parotid Gland / surgery. Parotid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Cysts / surgery. Diagnostic Errors. Female. Humans. Incidental Findings. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / surgery. Male. Middle Aged. Parotid Diseases / surgery. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 19962123.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Mueller SB, Micke O, Herbst H, Schaefer U, Willich N: Alpha-fetoprotein-positive carcinoma of the pancreas: a case report. Anticancer Res; 2005 May-Jun;25(3A):1671-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of a 19-year-old male with an alpha-fetoprotein (AFP)-producing acinar cell carcinoma of the pancreas.
  • Tumour markers other than AFP were normal.
  • Initially, the tumour showed a good response to irradiation and 5-fluorouracil (5-FU) application, and therapy showed sufficient local control.
  • The patient died 18 months after the initial therapy due to general tumour progression.
  • Originally, AFP was thought to be specific to hepatocellular carcinoma and germ cell tumours.
  • Rare cases of acinar cell carcinomas of the pancreas were found to express AFP.
  • [MeSH-major] Pancreatic Neoplasms / metabolism. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033080.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


32. Patterson KI, Brummer T, Daly RJ, O'Brien PM: DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs. Biochim Biophys Acta; 2010 Sep;1803(9):1003-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, overexpression of DUSP26 in MCF10A epithelial cells suppressed colony formation and acinar growth in 3D culture, effects dependent on its phosphatase activity, while knockdown of DUSP26 in HOSE17.1 cells enhanced colony formation and cellular proliferation.
  • DUSP26 mRNA expression was reduced in neuroblastoma, brain and ovarian cancer cell lines.
  • Consistent with epigenetic silencing of DUSP26, expression was enhanced by treatment of cells with 5-aza-2-deoxycitidine and trichostatin A, and a CpG island upstream of the DUSP26 transcriptional start site was variably methylated in cancer cell lines.
  • In addition, they indicate that DUSP26 may function as a tumour suppressor in particular cancers.
  • [MeSH-major] Cell Proliferation. Dual-Specificity Phosphatases / physiology. Epithelial Cells / physiology. Extracellular Signal-Regulated MAP Kinases / metabolism. Mitogen-Activated Protein Kinase Phosphatases / physiology
  • [MeSH-minor] Animals. CHO Cells. COS Cells. Cells, Cultured. Cercopithecus aethiops. CpG Islands / genetics. Cricetinae. Cricetulus. Gene Knockdown Techniques. Genes, Tumor Suppressor / physiology. Humans. Phosphorylation / physiology

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20347885.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP26 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases
  •  go-up   go-down


33. Smukalla K, Kalinski T, Motsch C: [Distant metastases on acinic cell carcinoma of the parotid gland after 12 years symptom-free interval]. Laryngorhinootologie; 2006 Aug;85(8):586-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distant metastases on acinic cell carcinoma of the parotid gland after 12 years symptom-free interval].
  • Acinic cell carcinoma of parotid gland as cause of distant metastases are rare.
  • The patient was a 60-year-old woman who had in 1993 a acinic cell carcinoma of right parotid gland.
  • Tumour can be resected through total parotidectomy with facial nerve anastomosis and modified radical neck dissection (T (3) N (2b) M (0)).
  • Since the operation the patient has remained symptom-free without any sign of tumour recurrence.
  • Histologically and immunohistochemically the diagnosis of distant metastase on acinic carcinoma of the parotid gland was confirmed.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Acinar Cell / secondary. Manubrium. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Female. Follow-Up Studies. Humans. Middle Aged. Neck Dissection. Neoplasm Staging. Osteolysis / diagnosis. Osteolysis / pathology. Osteolysis / surgery. Parotid Gland / pathology. Parotid Gland / surgery. Radionuclide Imaging. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883494.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B: Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas. J Clin Pathol; 2008 Jan;61(1):49-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry showed that TBX4 expression could be seen in both centroacinar cells and small ducts in normal pancreas and tumour cells in 5/5 (100%) well differentiated, 35/38 (92.1%) moderately differentiated, and 11/18 (61.1%) poorly differentiated PDAC tissues with different staining intensity.
  • However, in normal acinar cells and tumour cells in the other 3/38 (7.9%) moderately differentiated and 7/18 (38.9%) poorly differentiated PDAC tissues, there was no visible TBX4 expression.
  • In addition, there was obvious morphology difference between TBX4 negatively stained and positively stained tumour cells, which suggests different cellular origins.
  • Strong expression of HSP60 could be seen in both acinar cells and small ducts in normal pancreas tissues and tumour cells in PDAC tissues except for islets and tumour stoma; no correlation was found between HSP60 expression and differentiation of PDAC tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Female. HSP40 Heat-Shock Proteins / metabolism. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Pancreas / metabolism. Proteomics. T-Box Domain Proteins / metabolism. Trypsin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17412869.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HSP40 Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / T-Box Domain Proteins; 0 / TBX4 protein, human; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


35. Dewald GW, Smyrk TC, Thorland EC, McWilliams RR, Van Dyke DL, Keefe JG, Belongie KJ, Smoley SA, Knutson DL, Fink SR, Wiktor AE, Petersen GM: Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. Mayo Clin Proc; 2009 Sep;84(9):801-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas.
  • OBJECTIVE: To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas.
  • PATIENTS AND METHODS: Between April 4, 2007, and December 4, 2008, interphase FISH was used to study paraffin-embedded preparations of tissue obtained from 18 patients listed in the Mayo Clinic Biospecimen Resource for Pancreas Research with a confirmed diagnosis of acinar cell carcinoma, ductal adenocarcinoma, islet cell carcinoma, or pancreas without evidence of neoplasia.
  • RESULTS: FISH abnormalities were observed in 12 (80%) of 15 patients with pancreatic cancer: 5 of 5 patients with acinar cell carcinoma, 5 of 5 patients with ductal adenocarcinoma, and 2 (40%) of 5 patients with islet cell carcinoma.
  • All 3 specimens of pancreatic tissue without neoplasia had normal FISH results.
  • Gains of CTNNB1 due to trisomy 3 occurred in each tumor with acinar cell carcinoma but in none of the other tumors in this study.
  • CONCLUSION: FISH abnormalities of CTNNB1 due to trisomy 3 were observed only in acinar cell carcinoma.
  • FISH abnormalities of genes implicated in familial cancer, tumor progression, and the 5-fluorouracil pathway were common but were not associated with specific types of pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4428-33 [15231651.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1337-42 [9579843.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):752-61 [15696124.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1766-73 [16030115.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Genet Med. 2006 Jan;8(1):16-23 [16418595.001]
  • [Cites] Cancer Invest. 2006 Feb;24(1):98-105 [16466998.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):704-10 [16614112.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):272-9 [17638662.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 1;178(1):26-35 [17889705.001]
  • [Cites] Cytogenet Genome Res. 2007;118(2-4):148-56 [18000365.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Pancreatology. 2008;8(2):110-25 [18382097.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):409-16 [10667595.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):856-62 [11054068.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3946-51 [11099324.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Curr Probl Cancer. 2002 Jul-Aug;26(4):176-275 [12399802.001]
  • [Cites] J Pathol. 2003 Apr;199(4):453-61 [12635136.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] Surgery. 2008 Aug;144(2):141-8 [18656619.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1727-33 [18515795.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] World J Surg. 2009 Jan;33(1):104-10 [19011933.001]
  • (PMID = 19720778.001).
  • [ISSN] 1942-5546
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA102701; United States / NCI NIH HHS / CA / P50 CA102701-07; United States / NCI NIH HHS / CA / R01 CA097075; United States / NCI NIH HHS / CA / R01 CA97075
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2735430
  •  go-up   go-down


36. de Araújo VC, Furuse C, Cury PR, Altemani A, de Araújo NS: STAT3 expression in salivary gland tumours. Oral Oncol; 2008 May;44(5):439-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results showed that, in normal salivary gland, STAT3 was expressed in cytoplasm and STAT3P in nuclei of all tissue cells, except in large mucous acinar cells for which both antibodies were negative.
  • The most important one was the presence of STAT3 in the nuclei of the malignant tumour cells, most evident in the cribriform-type of adenoid cystic carcinoma.
  • The presence of STAT3 in the nuclei of malignant salivary gland tumours may represent an important event in oncogenesis probably contributing to tumour cell proliferation while blocking apoptosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. STAT3 Transcription Factor / metabolism. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826306.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / STAT3 Transcription Factor
  •  go-up   go-down


37. Aleksic T, Baumann B, Wagner M, Adler G, Wirth T, Weber CK: Cellular immune reaction in the pancreas is induced by constitutively active IkappaB kinase-2. Gut; 2007 Feb;56(2):227-36
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In these double transgenic animals, doxycycline treatment induced expression of IKK2-EE (IKK2(CA)) in pancreatic acinar cells resulting in moderate activation of the IkappaB kinase complex, as measured by the immune complex kinase assay, and up to 200-fold activation of the transgene expression cassette, as detected by luciferase assay.
  • Increased mRNA levels of tumour necrosis factor alpha and RANTES were detected in pancreatic acinar cells.
  • IKK2(CA) in pancreatic acinar cells increases tissue damage of secretagogue induced experimental pancreatitis underlining the proinflammatory role of the IKK/NF-kappaB pathway in this disease.
  • [MeSH-minor] Animals. B-Lymphocytes / immunology. Ceruletide / immunology. Chemokine CCL5 / analysis. Doxycycline / immunology. Enzyme Activation. Gene Expression / genetics. Immunohistochemistry / methods. Luciferases / metabolism. Macrophages / immunology. Mice. Mice, Inbred C57BL. Mice, Inbred DBA. Mice, Transgenic. NF-kappa B / genetics. NF-kappa B / metabolism. RNA, Messenger / analysis. Transgenes / immunology. Tumor Necrosis Factor-alpha / analysis

  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Mar;118(3):573-81 [10702209.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 1):G1402-14 [9843778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4615-20 [10758165.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1208-28 [10833496.001]
  • [Cites] Pancreas. 2000 Jul;21(1):22-31 [10881929.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7963-8 [10859354.001]
  • [Cites] Methods Enzymol. 2000;327:401-21 [11044999.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1209-18 [11054378.001]
  • [Cites] DNA Cell Biol. 2000 Nov;19(11):639-45 [11098215.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3452-7 [11151876.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):420-30 [9922324.001]
  • [Cites] Int J Pancreatol. 1999 Jun;25(3):251 [10453425.001]
  • [Cites] Am J Physiol. 1999 Sep;277(3 Pt 1):G678-86 [10484394.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1322-9 [16286924.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):286-93 [11159909.001]
  • [Cites] N Engl J Med. 2001 Mar 8;344(10):732-8 [11236777.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3595-8 [11325826.001]
  • [Cites] Science. 2001 Aug 24;293(5534):1495-9 [11520989.001]
  • [Cites] Sci STKE. 2001 Aug 28;2001(97):pe1 [11698579.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):448-57 [11832459.001]
  • [Cites] Sci STKE. 1999 Oct 26;1999(5):RE1 [11865184.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S81-96 [11983155.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1898-912 [12055597.001]
  • [Cites] Gut. 2002 Jul;51(1):1-4 [12077078.001]
  • [Cites] Digestion. 2002;66(4):237-45 [12592100.001]
  • [Cites] Nat Med. 2003 May;9(5):575-81 [12692538.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):698-704 [12808617.001]
  • [Cites] Pancreas. 2003 Jul;27(1):14-9 [12826900.001]
  • [Cites] Pancreas. 2003 Nov;27(4):297-300 [14576490.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1723-32 [14691290.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Feb;286(2):G204-13 [12958018.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2452-7 [14983030.001]
  • [Cites] Science. 2004 Jun 25;304(5679):1963-7 [15218148.001]
  • [Cites] Dig Dis Sci. 1995 Jul;40(7):1561-8 [7628283.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1295-304 [8657102.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1678-83 [8939850.001]
  • [Cites] Nucleic Acids Res. 1997 Jul 15;25(14):2723-9 [9207017.001]
  • [Cites] Gut. 1997 Aug;41(2):263-8 [9301509.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2022-7 [9329966.001]
  • [Cites] Science. 1997 Oct 31;278(5339):860-6 [9346484.001]
  • [Cites] Trends Cell Biol. 2000 Apr;10(4):129-33 [10740266.001]
  • (PMID = 16870717.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CCL5; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 888Y08971B / Ceruletide; EC 1.13.12.- / Luciferases; EC 2.7.11.10 / I-kappa B Kinase; N12000U13O / Doxycycline
  • [Other-IDs] NLM/ PMC1856776
  •  go-up   go-down


38. Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, Mansmann U, Heinemann V, Boeck S: Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol; 2010 Aug;31(4):351-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. C-Reactive Protein / metabolism. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. L-Lactate Dehydrogenase / blood. Palliative Care. Pancreatic Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Acinar Cell / blood. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / pathology. Female. Humans. Kinetics. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / blood. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 1996 Dec 30;15(24):2797-812 [8981687.001]
  • [Cites] Onkologie. 2003 Oct;26(5):462-7 [14605463.001]
  • [Cites] Oncology. 2007;73(1-2):41-51 [18334830.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Endoscopy. 1993 Jan;25(1):58-68 [8453928.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8 [18172650.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5918-22 [19029412.001]
  • [Cites] Eur J Surg Oncol. 2000 Aug;26(5):474-9 [11016469.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:145-9 [10436809.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4787-92 [17947726.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):114-20 [17272317.001]
  • [Cites] Oncology. 2008;75(1-2):120-6 [18784438.001]
  • [Cites] Oncology. 2007;73(3-4):221-7 [18424886.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16 [12577228.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):132-8 [18249033.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Somatic Cell Genet. 1979 Nov;5(6):957-71 [94699.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):547-50 [11801751.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1292-7 [18700899.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Future Oncol. 2008 Feb;4(1):41-50 [18240999.001]
  • [Cites] World J Surg. 2009 Apr;33(4):716-22 [19082654.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Cancer. 2009 Jun 15;115(12):2630-9 [19353729.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):195-9 [15999098.001]
  • [Cites] Jpn J Clin Oncol. 2008 Nov;38(11):755-61 [18845521.001]
  • (PMID = 20480409.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 9007-41-4 / C-Reactive Protein; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


39. Beytut E, Sözmen M, Ergínsoy S: Immunohistochemical detection of pulmonary surfactant proteins and retroviral antigens in the lungs of sheep with pulmonary adenomatosis. J Comp Pathol; 2009 Jan;140(1):43-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopically, the tumour was disseminated throughout the lungs and displayed acinar or papillary growth.
  • Retrovirus antigen (Jaagsiekte Sheep Retrovirus Capsid Protein, JSRV CA) was demonstrated in the cytoplasm of tumour cells in the lung and lymph nodes by immunohistochemistry.
  • SP-A and SP-B expression was localized to the apical cytoplasm of the neoplastic cells, whereas SP-C was most strongly expressed in the perinuclear area of the tumour cells.
  • In the lungs of two sheep, low numbers of tumour cells expressed Clara cell secretory protein (CCSP).
  • The nuclei of the neoplastic epithelial cells and of the germinal centre lymphocytes within the peribronchiolar lymphoid tissue expressed the proliferating cell nuclear antigen (PCNA).
  • A local T-cell response occurs within affected lungs.
  • [MeSH-minor] Animals. Antigens, CD3 / metabolism. Cytoplasm / metabolism. Cytoplasm / pathology. Lymph Nodes / metabolism. Lymph Nodes / pathology. Proliferating Cell Nuclear Antigen / metabolism. Sheep. T-Lymphocytes / immunology. T-Lymphocytes / pathology. Uteroglobin / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081577.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, Viral; 0 / Proliferating Cell Nuclear Antigen; 0 / Pulmonary Surfactant-Associated Protein A; 0 / Pulmonary Surfactant-Associated Protein B; 0 / Pulmonary Surfactant-Associated Protein C; 9060-09-7 / Uteroglobin
  •  go-up   go-down


40. Martínez-Romero C, Rooman I, Skoudy A, Guerra C, Molero X, González A, Iglesias M, Lobato T, Bosch A, Barbacid M, Real FX, Hernández-Muñoz I: The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol; 2009 Oct;219(2):205-13
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC) are associated with major changes in cell differentiation.
  • We hypothesized that Polycomb might play a role in preneoplastic states in the pancreas and in tumour development/progression.
  • To obtain mechanistic insights, Bmi1 expression in cells undergoing in vitro exocrine cell metaplasia and the effects of Bmi1 depletion in an acinar cancer cell line were studied.
  • We found that Bmi1 and Ring1B are expressed in pancreatic exocrine precursor cells during early development and in ductal and islet cells-but not acinar cells-in the adult pancreas.
  • Bmi1 expression was induced in acinar cells during acute injury, in acinar-ductal metaplastic lesions, as well as in pancreatic intraepithelial neoplasia (PanIN) and PDAC.
  • Bmi1 knockdown in cultured acinar tumour cells led to changes in the expression of various digestive enzymes.
  • Our results suggest that Bmi1 and Ring1B are modulated in pancreatic diseases and could contribute differently to tumour development.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / metabolism. Pancreatitis, Chronic / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / metabolism

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 19585519.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Bmi1 protein, mouse; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / transcription factor PTF1; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


41. Ayub SB, Dodge J: Lipid-rich variant of pancreatic endocrine neoplasms: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):829-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid-rich variant of pancreatic endocrine neoplasms: a case report.
  • BACKGROUND: Pancreatic endocrine neoplasms (PENs) are a well-defined and well-characterized group of tumors.
  • The cells in the cell block were immunoreactive (positive) for cytokeratin AE1/AE3, synaptophysin, and chromogranin A.
  • An elective resection of the tumor was performed, which confirmed the diagnosis of lipid-rich variant of PENs.
  • CONCLUSION: Its mimickers include adrenal cortical carcinoma, metastatic clear-cell renal cell carcinoma, clear-cell PEN, foamy gland pattern of pancreatic ductal carcinoma, solid pseudopapillary tumor, and acinar cell carcinoma.
  • The distinguishing morphologic and immunohistochemical features of each are described.
  • [MeSH-major] Endocrine Gland Neoplasms / pathology. Lipids / chemistry. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053550.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Lipids
  •  go-up   go-down


42. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 8 expression in salivary gland tumors. Head Neck Pathol; 2008 Sep;2(3):169-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine whether KLK8 is expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), in order to compare normal with tumor tissues.
  • Pleomorphic adenomas, adenoid cystic carcinomas, polymorphous low grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas, and adenocarcinomas NOS of both minor and major salivary glands were examined.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Kallikreins / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands, Minor / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Humans. Immunoenzyme Techniques

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2006 Mar;54(3):337-42 [16286664.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):167-72 [14710225.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Mol Cancer Res. 2004 May;2(5):257-80 [15192120.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Gene. 1998 Jun 15;213(1-2):9-16 [9714609.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Clin Chem. 1999 Jun;45(6 Pt 1):790-9 [10351987.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):1-22 [15911097.001]
  • [Cites] FEBS Lett. 2005 Dec 19;579(30):6879-84 [16337200.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):643-52 [16800725.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):653-63 [16800726.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):723-31 [16800733.001]
  • [Cites] Int J Biol Markers. 2006 Apr-Jun;21(2):106-10 [16847813.001]
  • [Cites] Tumour Biol. 2006;27(5):274-82 [16888409.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11763-70 [17178872.001]
  • [Cites] Int J Biol Markers. 2006 Oct-Dec;21(4):201-5 [17177156.001]
  • [Cites] Clin Chim Acta. 2007 May;381(1):78-84 [17382920.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):31852-64 [17823117.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):22-31 [17629406.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):7-18 [16897430.001]
  • [Cites] Trends Endocrinol Metab. 2000 Mar;11(2):54-60 [10675891.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):184-204 [11294823.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):806-11 [11309326.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Jul;1(2):182-90 [11901813.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1198-205 [12142373.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1045-57 [12437087.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):87-96 [12507964.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2223-7 [12727843.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jan;190(1):60-6 [14749636.001]
  • (PMID = 20614312.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK8 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2807567
  • [Keywords] NOTNLM ; Human kallikrein 8 / Immunohistochemistry / Kallikreins / Prognostic markers / Salivary gland tumors
  •  go-up   go-down


43. Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM: Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med; 2008 May;37(5):309-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study were to determine the expression of Mcm-2, Ki-67 and geminin in salivary gland (SG) tumours, and to evaluate their usefulness for diagnosis or for prediction of tumour behaviour.
  • There were 13 adenoid cystic carcinomas (ACC), 10 carcinoma ex pleomorphic adenomas (CEPA), 10 mucoepidermoid carcinomas (MEC), 10 polymorphous low-grade adenocarcinomas (PLGA), 10 pleomorphic adenomas (PA) and nine acinic cell carcinomas (AcCC).
  • LI did not correlate to tumour grade or outcome for any of the markers or tumour types.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cell Cycle Proteins / biosynthesis. Ki-67 Antigen / biosynthesis. Nuclear Proteins / biosynthesis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Cell Proliferation. Diagnosis, Differential. Female. Geminin. Humans. Immunoenzyme Techniques. Male. Microarray Analysis. Middle Aged. Minichromosome Maintenance Complex Component 2. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248354.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


44. Klimstra DS: Nonductal neoplasms of the pancreas. Mod Pathol; 2007 Feb;20 Suppl 1:S94-112
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonductal neoplasms of the pancreas.
  • Although the majority of pancreatic neoplasms are infiltrating ductal adenocarcinomas or other neoplasms with ductal differentiation, neoplasms with acinar, endocrine, mixed, or uncertain differentiation constitute a diverse and distinctive group.
  • The most common and best-characterized nonductal neoplasms are pancreatic endocrine neoplasm, acinar cell carcinoma, pancreatoblastoma, and solid pseudopapillary neoplasm.
  • This review details the clinical and pathologic features of these nonductal neoplasms, highlighting diagnostic criteria including the use of specific immunohistochemical stains to define the cellular differentiation of the neoplasms.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Adenoma, Islet Cell / pathology. Carcinoma, Acinar Cell / pathology. Carcinoma, Islet Cell / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486055.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Rubello D, Nanni C, Castellucci P, Rampin L, Farsad M, Franchi R, Mariani G, Menaldo G, Fanti S: Does 18F-FDG PET/CT play a role in the differential diagnosis of parotid masses. Panminerva Med; 2005 Sep;47(3):187-9
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At FDG PET/CT, 9 false positive cases were found (8 Warthin's tumours, 1 pleomorphic adenoma), 1 false negative (acinar cell carcinoma), 4 true negative (1 Warthin's tumour, 1 pleomorphic adenoma, 1 lymph epithelial cyst, 1 parotid inflammation) whereas there was no case of true positive.
  • [MeSH-major] Fluorodeoxyglucose F18. Parotid Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462726.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


46. Tonel E, Carbone A, Scirelli T, Bellone G, Emanuelli G: [Biological aspects of pancreatic cancer]. Minerva Med; 2005 Apr;96(2):87-94
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These molecular alterations, including overexpression of receptor-ligand systems, oncogene activation and loss of tumour suppressor genes, leads to a profound disturbance in cell cycle regulation and continuous growth.
  • The molecular findings are now integrated in a pancreatic tumour progression model, with genetically and morphological defined precursor lesions.
  • However, it remains unclear whether the initial target cells of this cancer develop from ductal or acinar cells.
  • This review will present recent emerging questions on the biology of pancreatic cancer with particular emphasis on the cell origin and tumour microenvironment.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Cytokines / physiology. Genes, Tumor Suppressor / physiology. Humans

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172578.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 41
  •  go-up   go-down


47. Mansfield A, Tafur A, Smithedajkul P, Corsini M, Quevedo F, Miller R: Mayo Clinic experience with very rare exocrine pancreatic neoplasms. Pancreas; 2010 Oct;39(7):972-5
MedlinePlus Health Information. consumer health - Rare Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mayo Clinic experience with very rare exocrine pancreatic neoplasms.
  • OBJECTIVES: Limited data are available to guide the management of very rare exocrine neoplasms of the pancreas (VREP).
  • The most commonly identified neoplasms were acinar cell carcinoma (n = 15), small cell carcinoma (n = 12), and squamous cell carcinoma (n = 8).
  • [MeSH-major] Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / therapy. Rare Diseases / mortality. Rare Diseases / therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Acinar Cell / mortality. Carcinoma, Small Cell / mortality. Carcinoma, Squamous Cell / mortality. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622706.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Scheble VJ, Braun M, Wilbertz T, Stiedl AC, Petersen K, Schilling D, Reischl M, Seitz G, Fend F, Kristiansen G, Perner S: ERG rearrangement in small cell prostatic and lung cancer. Histopathology; 2010 Jun;56(7):937-43
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERG rearrangement in small cell prostatic and lung cancer.
  • AIMS: Small cell prostatic cancer is a rare but aggressive disease.
  • Currently, its histogenetic origin is unclear and its distinction from metastatic small cell lung cancer is challenging.
  • The aim of our study was to determine whether the ERG rearrangement commonly observed in acinar prostatic cancer can distinguish small cell prostatic cancer from small cell lung cancer samples.
  • METHODS AND RESULTS: We assessed 15 small cell prostatic cancers and 22 small cell lung cancers for ERG rearrangement using fluorescence in situ hybridization.
  • ERG rearrangement occurred in 86% of small cell prostatic cancers but in none of the small cell lung cancers and was the best marker to differentiate between both tumours (P < 0.0001).
  • CONCLUSIONS: The ERG rearrangement is commonly observed in small cell prostatic cancer, supporting the hypothesis that ERG rearrangement occurs in aggressive prostatic cancers.
  • Furthermore, the ERG rearrangement is the most significant marker to differentiate between small cell prostatic cancer and small cell lung cancer.
  • Moreover, our data suggest that small cell prostatic cancer is not a tumour entity on its own, but a dedifferentiated variant of common acinar prostatic cancer.
  • [MeSH-major] Carcinoma, Small Cell / genetics. Gene Rearrangement. Lung Neoplasms / genetics. Prostatic Neoplasms / genetics. Trans-Activators / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Chi-Square Distribution. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2010 Oct;57(4):633; author reply 633-4 [20955388.001]
  • (PMID = 20636794.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / ERG protein, human; 0 / Trans-Activators
  •  go-up   go-down


49. Illyés G, Luczay A, Benyó G, Kálmán A, Borka K, Köves K, Rácz K, Tulassay T, Schaff Z: Cushing's syndrome in a child with pancreatic acinar cell carcinoma. Endocr Pathol; 2007;18(2):95-102
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's syndrome in a child with pancreatic acinar cell carcinoma.
  • A case of pancreatic acinar cell tumor (ACC) is presented in a 10-year-old boy.
  • The tumor manifested clinically with Cushing's syndrome, high serum adrenocorticotropic hormone (ACTH) and cortisol concentrations.
  • Periodic acid Schiff positive cytoplasmic granules, trypsinogen, keratins, alpha-1-antitrypsin, and AFP were identified in the tumor cells.
  • Using immunochemiluminometric assay, a high quantity of ACTH was found in the fresh frozen tumor extract.
  • Combined radiochemotherapy was temporarily effective in reducing the tumor mass and serum AFP.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Cushing Syndrome / etiology. Pancreatic Neoplasms / complications

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):249-57 [10952408.001]
  • [Cites] Arch Dis Child. 1988 Dec;63(12):1494-6 [2852926.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):104-8 [10839610.001]
  • [Cites] Pediatr Surg Int. 2001 Nov;17(8):614-20 [11727051.001]
  • [Cites] Neuroscience. 1990;37(1):31-44 [1978740.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):828-30 [1377164.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(3):265-70 [1689089.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] Acta Radiol. 2003 Jan;44(1):103-6 [12631008.001]
  • [Cites] Radiat Med. 1999 Sep-Oct;17(5):365-8 [10593288.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):47-52 [11466723.001]
  • [Cites] J Clin Pathol. 1996 Nov;49(11):952-4 [8944621.001]
  • [Cites] Br Poult Sci. 1998 Mar;39(1):123-7 [9568309.001]
  • [Cites] Histochem Cell Biol. 2003 May;119(5):405-13 [12743826.001]
  • [Cites] Virchows Arch. 1994;424(5):485-90 [8032529.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S83-7 [11762358.001]
  • [Cites] Eur J Endocrinol. 1998 Apr;138(4):436-9 [9578513.001]
  • [Cites] Ultrastruct Pathol. 2000 Jul-Aug;24(4):227-41 [11013963.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Pancreas. 2006 Oct;33(3):311-2 [17003655.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Gut. 1995 Oct;37(4):544-51 [7489943.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1671-4 [16033080.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(3):231-2 [9161503.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] Infect Immun. 2002 Nov;70(11):6068-74 [12379683.001]
  • [Cites] JOP. 2004 May;5(3):151-4 [15138338.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • [Cites] Hepatogastroenterology. 1992 Jun;39(3):282-6 [1380476.001]
  • [Cites] Regul Pept. 2004 Dec 15;123(1-3):209-16 [15518914.001]
  • (PMID = 17917000.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


50. Frankel WL: Update on pancreatic endocrine tumors. Arch Pathol Lab Med; 2006 Jul;130(7):963-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endocrine tumors of the pancreas represent 1% to 2% of all pancreatic neoplasms.
  • The morphologic spectrum of these tumors can be variable, and the differential diagnosis includes chronic pancreatitis with neuroendocrine hyperplasia, ductal adenocarcinoma, solid pseudopapillary tumor, acinar cell carcinoma, and pancreatoblastoma.
  • It is important to be aware that unusual morphologic variants of pancreatic endocrine tumors are common, and immunohistochemical stains can help avoid misdiagnosis.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Diagnosis, Differential. Humans. Islets of Langerhans / pathology. Neoplasms, Germ Cell and Embryonal / diagnosis. Pancreatitis, Chronic / diagnosis. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831051.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


51. Gürbüz Y, Yildiz K, Aydin O, Almaç A: Immunophenotypical profiles of salivary gland tumours: a new evidence for their histogenetic origin. Pathologica; 2006 Apr;98(2):147-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 30 cases of salivary gland tumours (18 pleomorphic adenomas, 8 Warthin's tumours, 2 basal cell adenomas, 2 acinic cell carcinomas) were included in our study.
  • SMA was not detected in Warthin's tumour (p < 0.0001).
  • CK14 was found in all tumours except acinic cell carcinomas (p < 0.0001).
  • CK10 immunoreactivity was observed in 5 Warthin's tumour.
  • Immunophenotypic profile of Warthin's tumour is suggestive of an embryological remnant origin.
  • [MeSH-major] Actins / analysis. Keratins / analysis. Neoplasm Proteins / analysis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenolymphoma / chemistry. Adenolymphoma / pathology. Adenoma / chemistry. Adenoma / pathology. Adenoma, Pleomorphic / chemistry. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / chemistry. Carcinoma, Acinar Cell / pathology. Humans. Immunophenotyping. Organ Specificity. Protein Isoforms / analysis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929788.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Actins; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 68238-35-7 / Keratins
  •  go-up   go-down


52. Aresu L, Pregel P, Zanetti R, Caliari D, Biolatti B, Castagnaro M: E-cadherin and β-catenin expression in canine colorectal adenocarcinoma. Res Vet Sci; 2010 Dec;89(3):409-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • E-cadherin and its associated cytoplasmic proteins, including β-catenin, have been examined as potential oncogenic markers due to the significant correlation between tumour dedifferentiation and the invasive capacity of epithelial tumours.
  • In the intestinal mucosa of noncancerous areas, epithelial cells demonstrated equally strong membranous expression of E-cadherin and β-catenin localised to the cell-cell junctions.
  • The down-regulation of both E-cadherin and β-catenin was correlated with decreased differentiation and increased tumour grade.
  • In addition, the expression of β-catenin was correlated with tumour size.
  • These results suggest that dysfunction of the E-cadherin-catenin complex starts in the early stages of carcinogenesis and that the disruption of the tissue architecture is progressively associated with the invasion of the tumour.
  • [MeSH-major] Adenocarcinoma / veterinary. Cadherins / metabolism. Colorectal Neoplasms / veterinary. Dog Diseases / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Animals. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Dogs. Down-Regulation. Female. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20457460.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


53. Cavallini A, Falconi M, Bortesi L, Crippa S, Barugola G, Butturini G: Pancreatoblastoma in adults: a review of the literature. Pancreatology; 2009;9(1-2):73-80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatoblastoma is a very uncommon neoplasm in adults and its management represents a great challenge with regards to different treatment options.
  • CONCLUSION: Pancreatoblastoma is a rare neoplasm in adults.
  • The differential diagnosis includes nonfunctional pancreatic endocrine tumor, acinar cell carcinoma, solid pseudopapillary tumor and adenocarcinoma.
  • [MeSH-major] Carcinoma, Neuroendocrine. Pancreatic Neoplasms

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077457.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


54. Andreadis D, Epivatianos A, Mireas G, Nomikos A, Poulopoulos A, Yiotakis J, Barbatis C: Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours. J Laryngol Otol; 2006 Apr;120(4):298-304
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In normal and inflamed salivary gland samples, E-cadherin was expressed at the membrane of acinar, myoepithelial and ductal cells located at cell-cell contact points.
  • Furthermore, a weak to moderate loss of expression which was related to tissue tumour subtype was seen in malignant tumours such as: adenoid cystic carcinomas; polymorphous low-grade adenocarcinomas; acinic cell carcinomas; and mucoepidermoid low-grade, epithelial-myoepithelial, lymphoepithelial and squamous low-grade carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Adenoid Cystic / chemistry. Carcinoma, Ductal / chemistry. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623973.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


55. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol; 2006 Jan;42(1):57-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C-KIT (CD117), a tyrosine kinase receptor, is involved in the growth and development of normal tissues and some types of neoplasms.
  • In addition five samples of chronic submandibular sialadenitis, five normal minor salivary glands and parotid or submandibular gland tissue adjacent to benign tumour were also studied.
  • C-KIT expression was observed in cases of adenoid cystic, acinic cell polymorphous low grade, epithelial-myoepithelial, carcinosarcoma and basal cell adenocarcinomas, as in luminal cells of pleomorphic adenomas, in serous acinar and only in intercalated and a small number of striated ductal cells of inflammatory salivary gland tissue, whereas normal salivary lobules were generally negative except a weak positivity of intercalated cells.
  • Contrary to other reports, this study suggests that, C-KIT protein does not appear to be an exclusively specific marker for benign or malignant salivary gland neoplasms, but may be useful in differential diagnosis of adenoid cystic carcinoma from polymorphous low grade adenocarcinoma.
  • Furthermore its expression in serous acinar cells in sialadenitis and intercalated ductal cells in normal and inflammatory lesions may indicate a possible participation in pathogenesis of both neoplastic and non-neoplastic salivary gland diseases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis. Salivary Gland Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


56. Klipin M, Sparaco A, Omoshoro-Jones J, Smith MD: Acinar cell carcinoma--a rare tumour of the pancreas. S Afr J Surg; 2008 Aug;46(3):88
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma--a rare tumour of the pancreas.
  • [MeSH-major] Carcinoma, Acinar Cell / therapy. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807305.001).
  • [ISSN] 0038-2361
  • [Journal-full-title] South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie
  • [ISO-abbreviation] S Afr J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


57. Chacra ZA, Baig K, Al-Dhahri S, Zeitouni AG: Giant cystic parapharyngeal space tumour. J Otolaryngol; 2005 Aug;34(4):244-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cystic parapharyngeal space tumour.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Pharyngeal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048694.001).
  • [ISSN] 0381-6605
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


58. Liu KL, Teng YC, Tien YW, Lin JT: Elevated alpha-fetoprotein and a pancreatic tumour. Gut; 2008 Apr;57(4):434, 462
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated alpha-fetoprotein and a pancreatic tumour.
  • [MeSH-major] Carcinoma, Acinar Cell / blood. Pancreatic Neoplasms / blood. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334655.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down






Advertisement